PIM
PCRX icon

Partner Investment Management’s Pacira BioSciences PCRX Stock Holding History

Partner Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,291
Closed -$317K – 92
2019
Q2 		$317K Buy
7,291
+4,118
+130% +$175K 0.44% 61
2019
Q1 		$121K Sell
3,173
-2,978
-48% -$116K 0.17% 79
2018
Q4 		$265K Sell
6,151
-24,882
-80% -$1.16M 0.35% 64
2018
Q3 		$1.52M Sell
31,033
-7,211
-19% -$312K 1.3% 32
2018
Q2 		$1.23M Buy
38,244
+14,446
+61% +$499K 1.18% 36
2018
Q1 		$741K Buy
+23,798
New +$847K 0.84% 46
2017
Q3 		– Sell
-36,119
Closed -$1.72M – 99
2017
Q2 		$1.72M Buy
36,119
+1,906
+6% +$88.4K 2.51% 13
2017
Q1 		$1.56M Buy
34,213
+7,523
+28% +$325K 2.05% 18
2016
Q4 		$862K Buy
+26,690
New +$891K 1.35% 28

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return